Travis Motley, DPM
Podiatrist · Fort Worth, TXNPI 1003850991
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Synthes GmbH at 49.5% of the total. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $362.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Synthes GmbH$13K
- Smith+Nephew$8K
- Nextremity Solutions Inc.$2K
- Arthrosurface Incorporated$792
- Anika Therapeutics, Inc.$674
- Integra Lifesciences Corporation$491
- plus $2K from 12 others
Across 117 payments — averaging $7372.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotissue Holdings Inc.$620K
- Endo Pharmaceuticals Inc.$188K
- Smith+Nephew$55K
What the payments were for
- Consulting fees$3,29513%
- Speaking & faculty fees$13,59954%
- Travel & lodging$6,02024%
- Food & beverage$1,9998%
- Other$4912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Synthes GmbH | 22 | $12,586 |
| Smith+Nephew | 19 | $7,722 |
| Nextremity Solutions Inc. | 1 | $1,635 |
| Arthrosurface Incorporated | 2 | $792 |
| Anika Therapeutics, Inc. | 2 | $674 |
| Integra Lifesciences Corporation | 1 | $491 |
| Biotissue Holdings Inc. | 1 | $359 |
| Pylant Medical | 4 | $264 |
| Stryker | 3 | $222 |
| Zimmer Biomet | 4 | $178 |
| Bioventus LLC | 1 | $140 |
| Medartis Inc. | 1 | $121 |
| Polarityte, Inc. | 1 | $64 |
| Lifenet Health | 3 | $51 |
| Misonix Inc | 2 | $35 |
| Next Science LLC | 1 | $25 |
| Davol Inc. | 1 | $25 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oasis$5,120
- Santyl$4,053
- REGRANEX$2,786
- COLLAGENASE SANTYL$875
- HemiCAP Ankle$750
- HemiCAP$600
- ACell$491
- Prokera$359
- AmnioGraft$359
- AmnioGuard$359
- FLEXBAND$149
- Exogen$140
- APTUS$121
How this compares
$25,403 in reported general payments places this provider in the 90th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 11 | $34,512 |
| Ciclopirox | 26 | $871 |
| Gabapentin | 13 | $386 |
| Cephalexin | 27 | $139 |
| Methylprednisolone | 15 | $136 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $102 |
| Doxycycline Hyclate | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $7,722 | $34,51211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 470 podiatrist providers in Texas.
Other podiatrist in Fort Worth
- Brian CarpenterFort Worth$1.2M
- Alan GarrettFort Worth$185K
- Brady RhodesFort Worth$110K
- Gary LepowHouston$1M
- Wayne HurstCedar Park$625K
- Calvin RushingSunnyvale$452K
- Gregory JarygaFt Worth$175K
- Brandon LampeMesquite$154K
- Andrew SchneiderHouston$150K
- Patrick BriggsWebster$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.